LUND, SE / ACCESSWIRE / April 20, 2022 / Spago Nanomedical (STO:SPAGO.ST) (FRA:7UX.F)
Spago Nanomedical AB (publ) publishes its interim report for January-March 2022 on Tuesday, 27 April, 2022 at 08.00 CEST. On the same day, at 13.00 CEST, the company management presents the report and also provides an update on the company’s operations. The presentation will be held in English.
The presentation will be held at Penser Bank AB, Apelbergsgatan 27, Stockholm, and can be followed digitally, live and afterwards via the following link: https://youtu.be/pqfdg9mqf0E.
Registration for participation at Penser Bank is made to http://enews.penser.se/public/event/RegistrationForm/43435C427041465A4B7840.
For further information, please contact Mats Hansen, CEO Spago Nanomedical AB, +46 46 811 88, mats.hansen@spagonanomedical.se
Spago Nanomedical AB is a Swedish nanomedicines company in clinical development phase. The company´s development projects are based on a platform of polymeric materials with unique properties for more precise diagnosis and treatment of solid tumors. Spago Nanomedical´s share is listed on Nasdaq First North Growth Market (ticker: SPAGO). For further information, see www.spagonanomedical.se.
FNCA Sweden AB is the Certified Adviser of the company, +46 8 528 00 399, info@fnca.se.
Attachments
Spago Nanomedical presents its Q1 report and provides company update
SOURCE: Spago Nanomedical
View source version on accesswire.com:
https://www.accesswire.com/698132/Spago-Nanomedical-Presents-its-Q1-Report-and-Provides-Company-Update
Well-Capitalized Combined Company with Strong Financial Profile and 2023 Revenue of $246M, 28% from Recurring…
Chowis Co. Ltd. Skin, Hair and Scalp Solutions Provider Signs Agreement with Kolmar Korea to…
PORTLAND, OR / ACCESSWIRE / July 3, 2024 / Rose Villa Senior Living continues to…
Highlights:Total revenue of $9.9 million for Q1 2025, reflecting YoY growth of 31% from the…
Medical Device Developer & Investor Taps 4 Markets With Growth Projections of USD $39.1B by…
The round is led by Danish VC Dreamcraft, together with biotech investor Lundbeckfonden BioCapital and…